These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 19289382)

  • 1. Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnostic and prognostic investigation of patients with rheumatoid arthritis? A systematic review.
    Luime JJ; Colin EM; Hazes JM; Lubberts E
    Ann Rheum Dis; 2010 Feb; 69(2):337-44. PubMed ID: 19289382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of anti-modified citrullinated vimentin in rheumatoid arthritis.
    Maraina CH; Nurdayana AK; Rusni D; Azwany Y
    Int J Rheum Dis; 2010 Oct; 13(4):335-9. PubMed ID: 21199468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides.
    Mathsson L; Mullazehi M; Wick MC; Sjöberg O; van Vollenhoven R; Klareskog L; Rönnelid J
    Arthritis Rheum; 2008 Jan; 58(1):36-45. PubMed ID: 18163519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study.
    Syversen SW; Goll GL; van der Heijde D; Landewé R; Lie BA; Odegård S; Uhlig T; Gaarder PI; Kvien TK
    Ann Rheum Dis; 2010 Feb; 69(2):345-51. PubMed ID: 19648126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-MCV antibodies predict radiographic progression in Greek patients with very early (<3 months duration) rheumatoid arthritis.
    Barouta G; Katsiari CG; Alexiou I; Liaskos C; Varna A; Bogdanos DP; Germenis AE; Sakkas LI
    Clin Rheumatol; 2017 Apr; 36(4):885-894. PubMed ID: 27943044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature.
    Bartoloni E; Alunno A; Bistoni O; Bizzaro N; Migliorini P; Morozzi G; Doria A; Mathieu A; Lotzniker M; Allegri F; Riccieri V; Alpini C; Gabrielli A; Tampoia M; Gerli R;
    Autoimmun Rev; 2012 Sep; 11(11):815-20. PubMed ID: 22394488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of anti-mutated citrullinated vimentin, anti-cyclic citrullinated peptides, anti-glucose-6-phosphate isomerase and anti-keratin antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Chinese patients.
    Zhu T; Feng L
    Int J Rheum Dis; 2013 Apr; 16(2):157-61. PubMed ID: 23773638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis.
    Soós L; Szekanecz Z; Szabó Z; Fekete A; Zeher M; Horváth IF; Dankó K; Kapitány A; Végvári A; Sipka S; Szegedi G; Lakos G
    J Rheumatol; 2007 Aug; 34(8):1658-63. PubMed ID: 17611988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selected cyclic citrullinated peptides derived from the sequence of mutated and citrullinated vimentin (MCV) are targeted by different antibodies subclasses in patients with rheumatoid arthritis in Russian patients.
    Derganova O; Martinez-Gamboa L; Egerer K; Bang H; Fredenhagen G; Roggenbuck D; Esaulenko I; Burmester GR; Chernykh T; Feist E
    Clin Exp Rheumatol; 2014; 32(5):622-9. PubMed ID: 25189876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic utility of anti-cyclic citrullinated peptide and anti-modified citrullinated vimentin antibodies in rheumatoid arthritis.
    Keskin G; Inal A; Keskin D; Pekel A; Baysal O; Dizer U; Sengül A
    Protein Pept Lett; 2008; 15(3):314-7. PubMed ID: 18336364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis: compared with anti-CCP and rheumatoid factor, could anti-MCV be the next biomarker in the rheumatoid arthritis classification criteria?
    Zhu JN; Nie LY; Lu XY; Wu HX
    Clin Chem Lab Med; 2019 Oct; 57(11):1668-1679. PubMed ID: 31141478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis setting.
    van Heemst J; Trouw LA; Nogueira L; van Steenbergen HW; van der Helm-van Mil AH; Allaart CF; Serre G; Holmdahl R; Huizinga TW; Toes RE; van der Woude D
    Arthritis Res Ther; 2015 Oct; 17():276. PubMed ID: 26437716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic accuracy of anti-MCV and anti-CCP antibodies in rheumatoid arthritis: A meta-analysis.
    Lee YH; Bae SC; Song GG
    Z Rheumatol; 2015 Dec; 74(10):911-8. PubMed ID: 26111961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis.
    Wagner E; Skoumal M; Bayer PM; Klaushofer K
    Rheumatol Int; 2009 Sep; 29(11):1315-21. PubMed ID: 19184032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-MCV and anti-CCP antibodies-diagnostic and prognostic value in children with juvenile idiopathic arthritis (JIA).
    Lipinska J; Lipinska S; Kasielski M; Smolewska E
    Clin Rheumatol; 2016 Nov; 35(11):2699-2706. PubMed ID: 27457366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison between IgG- and IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis.
    Svärd A; Kastbom A; Söderlin MK; Reckner-Olsson Å; Skogh T
    J Rheumatol; 2011 Jul; 38(7):1265-72. PubMed ID: 21459947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies to mutated citrullinated vimentin and anti-cyclic citrullinated peptide antibodies in inflammatory bowel disease and related arthritis.
    Al-Jarallah K; Shehab D; Al-Attiyah R; Al-Azmi W; Al-Fadli A; Zafar Haider M; Panaccione R; Ghosh S
    Inflamm Bowel Dis; 2012 Sep; 18(9):1655-62. PubMed ID: 22114016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients.
    Snir O; Widhe M; Hermansson M; von Spee C; Lindberg J; Hensen S; Lundberg K; Engström A; Venables PJ; Toes RE; Holmdahl R; Klareskog L; Malmström V
    Arthritis Rheum; 2010 Jan; 62(1):44-52. PubMed ID: 20039432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis.
    Dejaco C; Klotz W; Larcher H; Duftner C; Schirmer M; Herold M
    Arthritis Res Ther; 2006; 8(4):R119. PubMed ID: 16859519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.